JP2017533275A - フィナフロキサシンおよびトリスを含む組成物 - Google Patents
フィナフロキサシンおよびトリスを含む組成物 Download PDFInfo
- Publication number
- JP2017533275A JP2017533275A JP2017542367A JP2017542367A JP2017533275A JP 2017533275 A JP2017533275 A JP 2017533275A JP 2017542367 A JP2017542367 A JP 2017542367A JP 2017542367 A JP2017542367 A JP 2017542367A JP 2017533275 A JP2017533275 A JP 2017533275A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- finafloxacin
- tris
- treatment
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (22)
- フィナフロキサシンおよびトリスを含む組成物。
- 前記組成物がトリスを0.001Mから0.2Mの濃度、好ましくは0.002Mから0.1Mの濃度、最も好ましくは0.01Mの濃度で含む、請求項1の組成物。
- 前記組成物が7.0から12.0のpH、好ましくは8.0から10.0のpH、最も好ましくは8.0から8.5のpHを有する、請求項1または2の組成物。
- 前記組成物が非経口適用のための薬学的に許容可能な組成物である、請求項1から3のいずれか1の組成物。
- 前記組成物がさらに薬学的補形剤を含む、請求項1から4のいずれか1の組成物。
- 前記組成物が塩化ナトリウムを0.4%から1.0%(w/v)の濃度、好ましくは0.6%から0.9%(w/v)の濃度、最も好ましくは0.7%から0.8%(w/v)の濃度で含む、請求項5の組成物。
- 前記組成物が200から700mOsm/kgの浸透圧、好ましくは260から390mOsm/kgの浸透圧、最も好ましくは270から350mOsmol/kgの浸透圧を有する、請求項1から6のいずれか1の組成物。
- 前記組成物がフィナフロキサシン一塩酸塩を含む、請求項1から7のいずれか1の組成物。
- 前記組成物がフィナフロキサシンを0.2g/lから50g/lの濃度、好ましくは0.4g/lから25g/lの濃度、最も好ましくは0.8g/lから13g/lの濃度で含む、請求項1から8のいずれか1の組成物。
- 前記組成物が1.6から6.4g/lのフィナフロキサシン、7から8g/lのNaCl、1から2g/lのトリスを含み、8.0から8.5のpHを有する、請求項1から9のいずれか1の組成物。
- 前記組成物が3.2g/lのフィナフロキサシン、7.8g/lのNaCl、1.21g/lのトリスを含み、8.25のpHを有する、請求項10の組成物。
- 細菌感染症の治療における使用のための、請求項4から11のいずれか1の組成物。
- 尿路感染症および腎盂腎炎の治療に使用する、請求項12の使用のための組成物。
- 腹腔内感染症の治療に使用する、請求項12の使用のための組成物。
- 皮膚および軟組織感染症の治療に使用する、請求項12の使用のための組成物。
- 糖尿病足病変感染症の治療に使用する、請求項12の使用のための組成物。
- 菌血症の治療に使用する、請求項12の使用のための組成物。
- 呼吸器感染症の治療に使用する、請求項12の使用のための組成物。
- 前立腺炎の治療に使用する、請求項12の使用のための組成物。
- 骨や関節の感染症の治療に使用する、請求項12の使用のための組成物。
- 哺乳類およびヒトを対象とする細菌感染症予防法において使用する、請求項4から11のいずれか1の組成物。
- 細菌感染症を治療するための医薬品の製造における、請求項4から11のいずれか1の組成物の、薬学的な有効量での使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102014115951.9A DE102014115951A1 (de) | 2014-11-03 | 2014-11-03 | Zusammensetzungen, die Finafloxacin und Tris enthalten |
DE102014115951.9 | 2014-11-03 | ||
PCT/IB2015/057729 WO2016071784A1 (en) | 2014-11-03 | 2015-10-09 | Compositions comprising finafloxacin and tris |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017533275A true JP2017533275A (ja) | 2017-11-09 |
JP6748339B2 JP6748339B2 (ja) | 2020-09-02 |
Family
ID=54337838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017542367A Active JP6748339B2 (ja) | 2014-11-03 | 2015-10-09 | フィナフロキサシンおよびトリスを含む組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10576088B2 (ja) |
EP (1) | EP3215125B1 (ja) |
JP (1) | JP6748339B2 (ja) |
CN (1) | CN107106486B (ja) |
DE (1) | DE102014115951A1 (ja) |
ES (1) | ES2738706T3 (ja) |
PL (1) | PL3215125T3 (ja) |
WO (1) | WO2016071784A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102015100068A1 (de) * | 2015-01-06 | 2016-07-07 | Merlion Pharmaceuticals Pte Ltd. | Finafloxacin zur verwendung bei der behandlung von harnwegsinfektionen |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19652239A1 (de) | 1996-12-16 | 1998-06-18 | Bayer Ag | Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen |
JP2005535644A (ja) * | 2002-06-26 | 2005-11-24 | ファルマシア コーポレイション | 安定な非経口パレコキシブ液体製剤 |
UY32758A (es) | 2009-07-02 | 2010-10-29 | Alcon Res Ltd | Composiciones y métodos para el tratamiento de infecciones ópticas, nasales u oftálmicas |
US9504691B2 (en) | 2012-12-06 | 2016-11-29 | Alcon Research, Ltd. | Finafloxacin suspension compositions |
US9884039B2 (en) * | 2013-04-05 | 2018-02-06 | Scpharmaceuticals Inc. | Pharmaceutical formulations for subcutaneous administration of furosemide |
-
2014
- 2014-11-03 DE DE102014115951.9A patent/DE102014115951A1/de not_active Withdrawn
-
2015
- 2015-10-09 US US15/523,680 patent/US10576088B2/en active Active
- 2015-10-09 JP JP2017542367A patent/JP6748339B2/ja active Active
- 2015-10-09 PL PL15784165T patent/PL3215125T3/pl unknown
- 2015-10-09 WO PCT/IB2015/057729 patent/WO2016071784A1/en active Application Filing
- 2015-10-09 ES ES15784165T patent/ES2738706T3/es active Active
- 2015-10-09 EP EP15784165.1A patent/EP3215125B1/en active Active
- 2015-10-09 CN CN201580059664.8A patent/CN107106486B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
DE102014115951A1 (de) | 2016-05-04 |
WO2016071784A1 (en) | 2016-05-12 |
EP3215125B1 (en) | 2019-07-03 |
PL3215125T3 (pl) | 2020-01-31 |
ES2738706T3 (es) | 2020-01-24 |
US20170326151A1 (en) | 2017-11-16 |
CN107106486A (zh) | 2017-08-29 |
CN107106486B (zh) | 2021-03-23 |
JP6748339B2 (ja) | 2020-09-02 |
US10576088B2 (en) | 2020-03-03 |
EP3215125A1 (en) | 2017-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2535928T3 (es) | Método para inhibir Clostridium difficile mediante la administración de oritavancina | |
JP7229999B2 (ja) | ダプトマイシン製剤 | |
JP2023540149A (ja) | 抗ウイルス化合物の製剤 | |
US20220160736A1 (en) | Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto | |
JP5653466B2 (ja) | フルニソリド含有粘膜適用組成物 | |
JP2018530578A (ja) | 組み合せ抗細菌組成物および短期抗細菌レジメン | |
AU2018230805B2 (en) | Antimicrobial compounds, compositions, and uses thereof | |
US20200188478A1 (en) | Pre-mixed, ready to use vancomycin compositions | |
JP2020520963A (ja) | 抑うつ障害の処置 | |
RU2542449C2 (ru) | Композиции и способы лечения рака мочевого пузыря | |
KR20180030479A (ko) | 레파뮬린의 주사가능한 약제학적 제형 | |
JP6748339B2 (ja) | フィナフロキサシンおよびトリスを含む組成物 | |
JP3502574B2 (ja) | 眼感染症治療用眼軟膏剤 | |
WO2013108180A1 (en) | Aqueous paracetamol composition for injection | |
JP6073202B2 (ja) | 静脈におけるウイルスの治療 | |
AU2019228913B2 (en) | Pharmaceutical composition with excellent storage stability | |
WO2004080429A2 (en) | Use of thiol-based compositions in ameliorating mucosal injury | |
TW200902092A (en) | Aliphatic acid-containing N-halogenated amino acid formulations | |
JP2009538822A5 (ja) | ||
CN106572982B9 (zh) | 具有泡腾剂的抗微生物组合物 | |
WO2014083071A1 (en) | Injectable liquid formulation of the combination of tramadol and paracetamol | |
US20230052601A1 (en) | Halo active aromatic sulfonamide pharmaceutical compositions for internal use | |
US10485805B2 (en) | Finafloxacin for use in the treatment of urinary tract infections | |
GB2573784A (en) | A stable aqueous hydroxycarbamide solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181004 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190626 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190927 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200129 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200218 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20200311 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200311 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200311 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200626 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6748339 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |